Cargando…

STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes

BACKGROUND: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that loss of STAG2 expression is a good prognostic i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Naheema S., Humayun-Zakaria, Nada, Goel, Anshita, Abbotts, Ben, Zeegers, Maurice P., Cheng, K.K., James, Nicholas D., Arnold, Roland, Bryan, Richard T., Ward, Douglas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051973/
https://www.ncbi.nlm.nih.gov/pubmed/35495284
http://dx.doi.org/10.1016/j.euros.2022.02.004
_version_ 1784696683732402176
author Gordon, Naheema S.
Humayun-Zakaria, Nada
Goel, Anshita
Abbotts, Ben
Zeegers, Maurice P.
Cheng, K.K.
James, Nicholas D.
Arnold, Roland
Bryan, Richard T.
Ward, Douglas G.
author_facet Gordon, Naheema S.
Humayun-Zakaria, Nada
Goel, Anshita
Abbotts, Ben
Zeegers, Maurice P.
Cheng, K.K.
James, Nicholas D.
Arnold, Roland
Bryan, Richard T.
Ward, Douglas G.
author_sort Gordon, Naheema S.
collection PubMed
description BACKGROUND: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that loss of STAG2 expression is a good prognostic indicator in NMIBC. OBJECTIVE: To confirm the relationship between STAG2 protein expression and clinical outcomes and tumour characteristics in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: IHC was used to determine STAG2 expression in 748 incident urothelial bladder cancers (UBCs) and recurrence-free, progression-free, and disease-specific survival were compared for patients with and without STAG2 loss. Exome and RNA sequencing were used to explore links between STAG2 loss and tumour molecular characteristics. RESULTS AND LIMITATIONS: STAG2 loss was observed in 19% of UBC patients and was 1.6-fold more common among female patients. Loss was frequent among grade 1 pTa tumours (40%), decreasing with stage and grade to only 5% among grade 3 pT2+ tumours. Loss was associated with fewer copy-number changes and less aggressive expression subtypes. In UBC, STAG2 loss was a highly significant prognostic indicator of better disease-free survival but was not independent of stage and grade. STAG2 loss was not a statistically significant predictor of NMIBC recurrence. STAG2 loss was significantly associated with better progression-free survival in NMIBC and appeared to be more prognostic for males than for females. CONCLUSIONS: A simple IHC-based STAG2 test shows promise for identifying NMIBC patients at lower risk of progression to MIBC for whom more conservative treatments may be suitable. PATIENT SUMMARY: A protein called STAG2 is frequently lost in early bladder cancers, most often in less aggressive tumours. STAG2 loss is easily measured and could be used as a biomarker to help guide treatment decisions.
format Online
Article
Text
id pubmed-9051973
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90519732022-04-30 STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes Gordon, Naheema S. Humayun-Zakaria, Nada Goel, Anshita Abbotts, Ben Zeegers, Maurice P. Cheng, K.K. James, Nicholas D. Arnold, Roland Bryan, Richard T. Ward, Douglas G. Eur Urol Open Sci Urothelial Cancer BACKGROUND: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that loss of STAG2 expression is a good prognostic indicator in NMIBC. OBJECTIVE: To confirm the relationship between STAG2 protein expression and clinical outcomes and tumour characteristics in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: IHC was used to determine STAG2 expression in 748 incident urothelial bladder cancers (UBCs) and recurrence-free, progression-free, and disease-specific survival were compared for patients with and without STAG2 loss. Exome and RNA sequencing were used to explore links between STAG2 loss and tumour molecular characteristics. RESULTS AND LIMITATIONS: STAG2 loss was observed in 19% of UBC patients and was 1.6-fold more common among female patients. Loss was frequent among grade 1 pTa tumours (40%), decreasing with stage and grade to only 5% among grade 3 pT2+ tumours. Loss was associated with fewer copy-number changes and less aggressive expression subtypes. In UBC, STAG2 loss was a highly significant prognostic indicator of better disease-free survival but was not independent of stage and grade. STAG2 loss was not a statistically significant predictor of NMIBC recurrence. STAG2 loss was significantly associated with better progression-free survival in NMIBC and appeared to be more prognostic for males than for females. CONCLUSIONS: A simple IHC-based STAG2 test shows promise for identifying NMIBC patients at lower risk of progression to MIBC for whom more conservative treatments may be suitable. PATIENT SUMMARY: A protein called STAG2 is frequently lost in early bladder cancers, most often in less aggressive tumours. STAG2 loss is easily measured and could be used as a biomarker to help guide treatment decisions. Elsevier 2022-03-04 /pmc/articles/PMC9051973/ /pubmed/35495284 http://dx.doi.org/10.1016/j.euros.2022.02.004 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Urothelial Cancer
Gordon, Naheema S.
Humayun-Zakaria, Nada
Goel, Anshita
Abbotts, Ben
Zeegers, Maurice P.
Cheng, K.K.
James, Nicholas D.
Arnold, Roland
Bryan, Richard T.
Ward, Douglas G.
STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes
title STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes
title_full STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes
title_fullStr STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes
title_full_unstemmed STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes
title_short STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes
title_sort stag2 protein expression in non–muscle-invasive bladder cancer: associations with sex, genomic and transcriptomic changes, and clinical outcomes
topic Urothelial Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051973/
https://www.ncbi.nlm.nih.gov/pubmed/35495284
http://dx.doi.org/10.1016/j.euros.2022.02.004
work_keys_str_mv AT gordonnaheemas stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes
AT humayunzakarianada stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes
AT goelanshita stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes
AT abbottsben stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes
AT zeegersmauricep stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes
AT chengkk stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes
AT jamesnicholasd stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes
AT arnoldroland stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes
AT bryanrichardt stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes
AT warddouglasg stag2proteinexpressioninnonmuscleinvasivebladdercancerassociationswithsexgenomicandtranscriptomicchangesandclinicaloutcomes